Analyzing genetic changes in different types of thyroid cancer
Official title: Observational Study Analysing the Transcriptome and Mutational Status of Thyroid Carcinomas of Follicular Origin with Different Degrees of Malignancy
Run by Irccs Synlab Sdn · NCT06878534 · Data updated 2026-11-12
This study is testing how genetic changes in different types of thyroid cancer can help improve diagnosis and treatment for adults with these cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Irccs Synlab Sdn Academic / other |
| Locations | 1 site (Naples) |
| Status | Recruiting |
| Started | March 13, 2023 |
| Main results expected | July 30, 2024 |
| Study ends | March 31, 2027 |
| Registry record updated | March 17, 2025 |
| Trial ID | NCT06878534 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients over 18 years old diagnosed with thyroid cancer of follicular origin.
✕Probably not a fit
Patients with thyroid cancer types other than follicular origin may not receive benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on thyroid cancers of follicular origin, particularly well-differentiated thyroid carcinomas like papillary and follicular types. It aims to analyze the transcriptome and mutational status of these cancers to understand their varying degrees of malignancy. By examining molecular alterations in key pathways, the study seeks to refine diagnostic criteria and improve treatment strategies for patients with thyroid cancer. The research will involve patients over 18 years old diagnosed with thyroid cancer of follicular origin.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic and treatment approaches for patients with thyroid cancer.
How similar studies have gone: Other studies have shown success in analyzing genetic alterations in thyroid cancers, indicating that this approach is promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of either sex aged \> 18 years with thyroid cancer of follicular origin. Exclusion Criteria: * Patients who do not fit the inclusion criteria.
Where it's running
-
Irccs Synlab Sdn
Naples, Italy Recruiting
Study contacts
- Principal investigator: Giovanni Smaldone — Irccs Synlab Sdn
- Study coordinator: Giovanni Smaldone, Master degree in biothecnology
- Email: giovanni.smaldone@synlab.it
- Phone: +39 0812408294
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.